首页> 外文期刊>Biosensors & Bioelectronics: The International Journal for the Professional Involved with Research, Technology and Applications of Biosensers and Related Devices >Detection of low-abundance biomarker lipocalin 1 for diabetic retinopathy using optoelectrokinetic bead-based immunosensing
【24h】

Detection of low-abundance biomarker lipocalin 1 for diabetic retinopathy using optoelectrokinetic bead-based immunosensing

机译:检测low-abundance生物标志物lipocalin 1使用optoelectrokinetic对糖尿病性视网膜病变bead-based immunosensing

获取原文
获取原文并翻译 | 示例
           

摘要

Early diagnosis of diabetic retinopathy (DR) is vital but challenging. DR is a common complication and a major cause of vision loss in patients with diabetes mellitus. Without appropriate medical intervention, visual impairment may become a great burden to our healthcare system. In clinical practice, the current diagnostic methods, such as fluorescence angiography and optical coherence tomography, remain constrained by non quantitative examinations and individual ophthalmologists' experiences. Late diagnosis often prevents early treatment. To address the constraints on current diagnostics, this study developed an optoelectrokinetic bead based immunosensing technique for detecting lipocalin 1 (LCN1), a DR biomarker. The concentration level of LCN1 in the tears of DR patients increases with DR severity. The immunoassay was dependent on the formation of sandwiched immunocomplexes on the particles. A secondary antibody labeled with dyes/quantum dots (QDs) was used to visualize the presence of the target antigens. Rapid electrokinetic patterning (REP), an optoelectrokinetic technique, was used to dynamically enhance the fluorescent signal by concentrating the modified particles. The limit of detection (LOD) of the technique could reach 110 pg/mL. Only 1.5 1.11, of a sample fluid was required for the measurement. Our results showed that highly sensitive and improved LOD is subjected to particle stacking, small particle size, and compact cluster. By labeling different particle sizes with dyes/QDs for LCN1 and TNF-alpha, we successfully used REP to detect the two DR biomarkers on the same platform. The development of an optoelectrokinetic bead-based immunosensing technique can provide new insights into diagnosing other low-abundance diseases in the future.
机译:糖尿病性视网膜病变(DR)的早期诊断但挑战至关重要。并发症和视力丧失的主要原因糖尿病患者。适当的医疗干预,视觉障碍可能会成为我们的一个很大的负担医疗保健系统。目前的诊断方法,如荧光血管造影术和光学相干断层扫描,仍然受到非量化考试和个人眼科医生的的经历。治疗。诊断,本研究开发了一个基于optoelectrokinetic珠immunosensing技术检测lipocalin 1 (LCN1)博士生物标志物。患者增加严重性博士的眼泪。免疫测定是依赖的形成夹immunocomplexes粒子。二次抗体与染料/量子点标记(量子点)被用来想象的存在目标抗原。(代表),一个optoelectrokinetic技术,是使用动态增强的荧光信号集中修改后的粒子。检测(LOD)可能达到的技术110 pg / mL。所需的测量。高度敏感的和改进的LOD受到粒子堆积,小粒子大小和紧凑的集群。量子点粒径染料/ LCN1和tnf,我们成功地代表检测使用两个博士生物标记物在同一平台。开发一个optoelectrokinetic bead-basedimmunosensing技术可以提供新的见解到其他low-abundance疾病诊断未来。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号